SynAct Pharma AB (8F8) AI Stock Analysis

SynAct Pharma AB

(Frankfurt:8F8)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low LeverageExtremely low leverage gives SynAct a relatively resilient capital structure for a clinical-stage company. Limited debt reduces interest and refinancing pressure, preserving more flexibility to direct available resources toward clinical development and future strategic financing.

Negative Factors

No Commercial RevenueWithout commercial revenue, SynAct has no established operating income stream to fund research, trials, or corporate costs. Its financial outlook therefore remains dependent on clinical progress and eventual monetization of resomelagon rather than on a diversified base of recurring sales.

SynAct Pharma AB (8F8) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 82.81M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -8.2
Beta (1Y): 0.46
Revenue Growth: ―
EPS Growth: -1.52%
Country: Germany
Employees: 8
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

SynAct Pharma AB Business Overview & Revenue Model

Company Description

SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently bei...

SynAct Pharma AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:8F8 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CANTA	70Outperform	SEK 451.68M	2.35	63.09%	―	―	―
SE:HNSA	55Neutral	SEK 4.00B	-5.00	―	―	-3.57%	8.84%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:BINV	43Neutral	SEK 357.32M	-0.73	-128.54%	―	-83.67%	-50.29%
SE:ACTI	42Neutral	SEK 105.31M	-10.14	-93.01%	―	―	54.60%
SE:FLERIE	40Underperform	SEK 1.27B	-1.16	-28.79%	―	-172.86%	-251.31%

* Healthcare Sector Average

Performance Comparison

DE:8F8 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:8F8	SynAct Pharma AB	1.45	-0.64	-30.46%
SE:HNSA	Hansa Biopharma	39.34	8.34	26.90%
SE:BINV	BioInvent International AB	5.43	-28.47	-83.98%
SE:FLERIE	InDex Pharmaceuticals Holding AB	13.90	-21.10	-60.29%
SE:ACTI	Active Biotech AB	4.00	-2.42	-37.76%
SE:CANTA	Cantargia AB	1.60	-1.97	-55.13%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

SynAct Pharma AB AI Stock Analysis